论文信息 - High and Early Rates of Cytogenetic and Molecular Response with Nilotinib 800 Mg Daily as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia in Chronic Phase: Results of a Phase 2 Trial of the GIMEMA CML Working Party - 字舞流文

High and Early Rates of Cytogenetic and Molecular Response with Nilotinib 800 Mg Daily as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia in Chronic Phase: Results of a Phase 2 Trial of the GIMEMA CML Working Party

M. Baccarani | G. Rosti | G. Martinelli | G. Saglio | F. Pane | N. Testoni | M. Breccia | G. Alimena | M. Tiribelli | F. Stagno | F. Castagnetti | G. Gugliotta | T. Intermesoli | B. Martino | M. Bocchia | F. Bartucci | A. Zaccaria | F. Palandri | L. Levato | A. Poerio | M. Cedrone | A. Capucci | M. Baccarani | Monday | Bruno | Martino